SRF388

Poster: IL-27 Expressed in the Tumor Microenvironment Is Correlated with PD-L1 Levels and Can Induce PD-L1 Expression on Immune and Tumor Cells

Society for Immunotherapy of Cancer Annual Meeting, November 2022

Publication: Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27

Cell Reports, October 2022

Poster: IL-27 Inhibits Immune Cell Reinvigoration Mediated by PD-(L)1 Blockade and Induces a Type 1 Interferon Gene Expression Signature Associated with Resistance to Therapy in Cancer Patients

ICIS2022, September 2022

Publication Abstract: IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma

Cancer Discovery, August 2022

Presentation: First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors

American Society of Clinical Oncology Annual Meeting, June 2022

Poster: Determination of a Recommended Phase 2 Dose (RP2D) for SRF388, a First-in-Class IL-27-Blocking Antibody, in Patients with Advanced Solid Tumors

American Association for Cancer Research Annual Meeting, April 2022

Poster: IL-27 signaling drives a type 1 interferon-like gene expression program of immunoregulatory pathways associated with cancer progression

Society for Immunotherapy of Cancer, November 2021

Poster: Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors

American Society of Clinical Oncology Annual Meeting, June 2021

Poster: IL-27 Signaling Serves as an Immunological Checkpoint for NK Cells to Promote Hepatocellular Carcinoma in Multiple Murine Models

American Association for Cancer Research Annual Meeting, April 2021

Publication: Serum IL27 in Relation to Risk of Hepatocellular Carcinoma in Two Nested Case-Control Studies

Cancer Epidemiology, Biomarker & Prevention, November 2020

Poster: Increased Serum Levels of EBI3 Are Associated with Poor Outcome in Hepatocellular Carcinoma Patients and SRF388, a First-in-Class IL-27 Blocking Antibody, Inhibits the Growth of Murine Liver Tumor

Society for Immunotherapy of Cancer Annual Meeting, November 2020

Video Presentation: Crystal Structure of IL-27 in Complex with SRF388, a First-in-Class IL-27 Blocking Antibody Under Evaluation in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

International Cytokine & Interferon Society Annual Meeting Conference, November 2020

Poster: Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody to counteract IL-27-mediated immunosuppression in this setting

American Association for Cancer Research Annual Meeting, June 2020